Valuation: Repare Therapeutics Inc.

Market Cap 112M 96.81M 90.85M 82.77M 156M 10.71B 158M 1.07B 417M 5.37B 421M 412M 17.87B P/E 2023
-3.28x
P/E 2024 -0.66x
Enterprise Value -38.78M -33.49M -31.43M -28.64M -53.8M -3.71B -54.59M -369M -144M -1.86B -146M -142M -6.18B EV / Sales 2023
1,707,888x
EV / Sales 2024 -1,779,624x
Free-Float
99.77%
Yield 2023 *
-
Yield 2024 -
1 day+0.76%
Current year+1.92%
Current year 2.5
Extreme 2.5
2.65
1 year 1.52
Extreme 1.52
2.66
3 years 0.89
Extreme 0.89
13.85
5 years 0.89
Extreme 0.89
35.04
10 years 0.89
Extreme 0.89
46.44
Manager TitleAgeSince
President - 2026-01-27
Director TitleAgeSince
Director/Board Member - 2026-01-27
Date Insider Type Main position Quantity % Market Cap.
1/28/26 Issuer sale

Chief Executive Officer

1,167,586 2.7085%
1/28/26
BVF Partners LP
TenderCompany 10,166,943 23.5846%
1/28/26 Issuer sale

Chairman

7,500 0.0174%
Change 5-day change 1-year change 3-year change Capi.($)
+0.76%-.--%+68.79%-72.19% 114M
+0.68%-1.01%+2.16%+18.05% 48.42B
+4.07%+3.34%+483.70%+609.03% 43.66B
+4.33%+4.09%+12.80%+88.48% 39.51B
+1.94%+1.06%+26.24%+12.10% 38.95B
-0.50%+0.85%+20.60%+58.18% 32.61B
-0.44%-3.14% - - 16.32B
+3.22%+1.09%+30.42%+133.64% 16.15B
-0.62%+0.29%+3.46%+25.58% 14.16B
+2.35%+7.16%+82.95%+41.92% 13.37B
Average +1.58%-0.31%+81.24%+101.64% 26.33B
Weighted average by Cap. +1.93%-0.62%+101.57%+147.41%

Financials

2023 2024
Net sales 51.13 44.17 41.45 37.76 70.95 4.89K 71.99 486.15 190.31 2.45K 191.96 187.81 8.15K 53.48 46.19 43.35 39.49 74.2 5.11K 75.29 508.44 199.03 2.56K 200.76 196.42 8.52K
Net income -93.8M -81.02M -76.03M -69.27M -130M -8.97B -132M -892M -349M -4.49B -352M -345M -14.95B -84.69M -73.15M -68.65M -62.54M -118M -8.1B -119M -805M -315M -4.06B -318M -311M -13.5B
Net Debt -220M -190M -179M -163M -306M -21.05B -310M -2.09B -820M -10.55B -827M -809M -35.1B -151M -130M -122M -111M -209M -14.42B -212M -1.43B -561M -7.23B -566M -554M -24.05B
Logo Repare Therapeutics Inc.
Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes RP-3467, a Phase 1 Polo ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor, and lunresertib, a PKMYT1 inhibitor.
Employees
129
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. RPTX Stock